Skip to content

ACER THERAPEUTICS INC.: 10-Q/A filed 2021-11-19

What ACER THERAPEUTICS INC. reported in its quarterly report amendment filed 2021-11-19 (fiscal Q2 2021): 37 published measures, 93 facts as tagged in accession 0001564590-21-057787.

This is an amendment. Values here are as tagged in the amendment; the original filing has its own page.

This filing

Form
10-Q/A (quarterly report amendment)
Filed
2021-11-19
Fiscal period
fiscal Q2 2021
Accession
0001564590-21-057787 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ACER THERAPEUTICS INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2021-06-3039,984,192USD
At 2020-12-3114,613,688USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2021-06-3035,147,054USD
At 2020-12-316,389,354USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2021-06-304,837,138USD
At 2021-03-317,311,512USD
At 2020-12-318,224,334USD
At 2020-06-3011,218,371USD
At 2020-03-3114,088,948USD
At 2019-12-3118,370,316USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2021-06-3022,128,332USD
At 2020-12-315,761,568USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2021-04-01 to 2021-06-30-3,069,037USD91
2021-01-01 to 2021-06-30-7,680,342USD181
2021-01-01 to 2021-03-31-4,611,305USD90
2020-04-01 to 2020-06-30-5,770,801USD91
2020-01-01 to 2020-06-30-10,719,507USD182
2020-01-01 to 2020-03-31-4,948,707USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2021-01-01 to 2021-06-309,242,939USD181
2020-01-01 to 2020-06-30-8,700,353USD182

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2021-01-01 to 2021-06-3015,222USD181

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2021-01-01 to 2021-06-30900,000USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2021-01-01 to 2021-06-307,139,047USD181
2020-01-01 to 2020-06-302,503,574USD182

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2021-01-01 to 2021-06-30-15,222USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2021-06-30-106,816,303USD
At 2020-12-31-99,135,961USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2021-04-01 to 2021-06-300USD91
2021-01-01 to 2021-06-300USD181
2020-04-01 to 2020-06-300USD91
2020-01-01 to 2020-06-300USD182

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2021-06-30112,666USD
At 2020-12-31130,081USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2021-01-01 to 2021-06-301,154,099USD181
2020-01-01 to 2020-06-301,270,912USD182

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2021-04-01 to 2021-06-30-3,629,795USD91
2021-01-01 to 2021-06-30-8,249,841USD181
2020-04-01 to 2020-06-30-5,769,886USD91
2020-01-01 to 2020-06-30-10,741,341USD182

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2021-06-3031,951,627USD
At 2020-12-316,441,029USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2021-06-3035,147,054USD
At 2020-12-316,145,546USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2021-06-301,808,455USD
At 2020-12-311,672,109USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2021-06-307,647,267USD
At 2020-12-317,647,267USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2021-04-01 to 2021-06-303,629,795USD91
2021-01-01 to 2021-06-309,149,841USD181
2020-04-01 to 2020-06-305,769,886USD91
2020-01-01 to 2020-06-3010,741,341USD182

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2021-04-01 to 2021-06-301,361,287USD91
2021-01-01 to 2021-06-303,367,192USD181
2020-04-01 to 2020-06-302,816,749USD91
2020-01-01 to 2020-06-305,139,653USD182

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2021-06-3014,310,244shares
At 2020-12-3113,233,137shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2021-06-3022,128,332USD
At 2020-12-315,761,568USD
At 2020-06-305,880,861USD
At 2019-12-3112,077,640USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2021-06-30200,000USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2021-06-30241,632USD
At 2020-12-31364,311USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2021-06-30280,147USD
At 2020-12-31264,925USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2021-06-30167,481USD
At 2020-12-31134,844USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2021-06-30272,632USD
At 2020-12-31395,311USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2020-12-31243,808USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2021-06-301,499,287USD
At 2020-12-313,781,101USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2021-01-01 to 2021-06-30-7,680,342USD181
2020-01-01 to 2020-06-30-10,719,507USD182

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2021-04-01 to 2021-06-302,268,508USD91
2021-01-01 to 2021-06-305,782,649USD181
2020-04-01 to 2020-06-302,953,137USD91
2020-01-01 to 2020-06-305,601,688USD182

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2021-01-01 to 2021-06-3032,637USD181
2020-01-01 to 2020-06-3035,419USD182

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2021-04-01 to 2021-06-30560,758USD91
2021-01-01 to 2021-06-30569,499USD181
2020-04-01 to 2020-06-30-915USD91
2020-01-01 to 2020-06-3021,834USD182

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2021-01-01 to 2021-06-303,139,047USD181
2020-01-01 to 2020-06-301,941,095USD182

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2021-04-01 to 2021-06-30100,000USD91
2021-01-01 to 2021-06-30100,000USD181
2020-04-01 to 2020-06-30100,000USD91
2020-01-01 to 2020-06-30100,000USD182

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2021-01-01 to 2021-06-30136,346USD181
2020-01-01 to 2020-06-30-126,624USD182

Inspect the source

Entity
ACER THERAPEUTICS INC. / CIK 0001069308
Captured
SEC response SHA-256
d41ecd9c66d537efeeb403c8604fe32734f808b5d83b00a9acc9f0ba72164b38

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001069308.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))